Elanco Animal Health Incorporated (NYSE: ELAN) Stock Competitors & Peer Comparison
See ELAN's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ELAN and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ELAN | $22.46 | -7.21% | 11B | 20.86 | $1.06 | N/A |
| TAK | $17.50 | +2.82% | 55.5B | 12.55 | $1.39 | +3.61% |
| HLN | $9.92 | -1.10% | 44.2B | 25.11 | $0.40 | +1.76% |
| TEVA | $35.38 | +1.62% | 41.2B | 12.06 | $2.93 | N/A |
| VTRS | $16.36 | +0.44% | 19.1B | 6.52 | $2.52 | +2.90% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.09 | -0.21% | 10.2B | 20.01 | $0.61 | +0.68% |
| LNTH | $100.93 | -0.14% | 6.6B | 16.97 | $5.95 | N/A |
| AMRX | $18.12 | +0.25% | 5.8B | 20.16 | $0.90 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ELAN vs TAK Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, TAK has a market cap of 55.5B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while TAK trades at $17.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas TAK's P/E ratio is 12.55. In terms of profitability, ELAN's ROE is -0.03%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ELAN is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TAK's competition here
Haleon plc (NYSE: HLN)
ELAN vs HLN Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, HLN has a market cap of 44.2B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while HLN trades at $9.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas HLN's P/E ratio is 25.11. In terms of profitability, ELAN's ROE is -0.03%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ELAN is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ELAN vs TEVA Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, TEVA has a market cap of 41.2B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while TEVA trades at $35.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas TEVA's P/E ratio is 12.06. In terms of profitability, ELAN's ROE is -0.03%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ELAN is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
ELAN vs VTRS Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, VTRS has a market cap of 19.1B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while VTRS trades at $16.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas VTRS's P/E ratio is 6.52. In terms of profitability, ELAN's ROE is -0.03%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ELAN is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
ELAN vs ITCI Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ELAN's ROE is -0.03%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ELAN is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
ELAN vs CTLT Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ELAN's ROE is -0.03%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ELAN is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ELAN vs RDY Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while RDY trades at $12.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas RDY's P/E ratio is 20.01. In terms of profitability, ELAN's ROE is -0.03%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ELAN is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ELAN vs LNTH Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while LNTH trades at $100.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas LNTH's P/E ratio is 16.97. In terms of profitability, ELAN's ROE is -0.03%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ELAN is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ELAN vs AMRX Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, AMRX has a market cap of 5.8B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while AMRX trades at $18.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas AMRX's P/E ratio is 20.16. In terms of profitability, ELAN's ROE is -0.03%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ELAN is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ELAN vs INDV Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while INDV trades at $38.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas INDV's P/E ratio is 10.64. In terms of profitability, ELAN's ROE is -0.03%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ELAN is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
ELAN vs SUPN Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while SUPN trades at $47.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas SUPN's P/E ratio is 15.57. In terms of profitability, ELAN's ROE is -0.03%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ELAN is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ELAN vs RGC Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while RGC trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas RGC's P/E ratio is -380.99. In terms of profitability, ELAN's ROE is -0.03%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ELAN is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ELAN vs BHC Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while BHC trades at $6.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas BHC's P/E ratio is 1.59. In terms of profitability, ELAN's ROE is -0.03%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ELAN is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ELAN vs DCPH Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ELAN's ROE is -0.03%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ELAN is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ELAN vs HCM Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while HCM trades at $12.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas HCM's P/E ratio is 4.69. In terms of profitability, ELAN's ROE is -0.03%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ELAN is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ELAN vs AVDL Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ELAN's ROE is -0.03%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ELAN is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
ELAN vs EMBCV Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ELAN's ROE is -0.03%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ELAN is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ELAN vs DVAX Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ELAN's ROE is -0.03%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ELAN is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ELAN vs ANIP Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while ANIP trades at $76.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas ANIP's P/E ratio is 9.52. In terms of profitability, ELAN's ROE is -0.03%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ELAN is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ANIP's competition here
Perrigo Company plc (NYSE: PRGO)
ELAN vs PRGO Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while PRGO trades at $12.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas PRGO's P/E ratio is 5.13. In terms of profitability, ELAN's ROE is -0.03%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ELAN is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check PRGO's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ELAN vs TARO Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas TARO's P/E ratio is 30.05. In terms of profitability, ELAN's ROE is -0.03%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ELAN is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ELAN vs HROW Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while HROW trades at $39.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas HROW's P/E ratio is 449.33. In terms of profitability, ELAN's ROE is -0.03%, compared to HROW's ROE of -0.34%. Regarding short-term risk, ELAN is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ELAN vs PAHC Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while PAHC trades at $34.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas PAHC's P/E ratio is 11.70. In terms of profitability, ELAN's ROE is -0.03%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ELAN is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
ELAN vs ALVO Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while ALVO trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas ALVO's P/E ratio is -11.21. In terms of profitability, ELAN's ROE is -0.03%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, ELAN is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
ELAN vs ETON Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while ETON trades at $43.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas ETON's P/E ratio is -637.14. In terms of profitability, ELAN's ROE is -0.03%, compared to ETON's ROE of -0.06%. Regarding short-term risk, ELAN is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
ELAN vs CRON Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while CRON trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas CRON's P/E ratio is 29.44. In terms of profitability, ELAN's ROE is -0.03%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ELAN is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ELAN vs PCRX Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, PCRX has a market cap of 984.2M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while PCRX trades at $24.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas PCRX's P/E ratio is 9.62. In terms of profitability, ELAN's ROE is -0.03%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ELAN is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check PCRX's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ELAN vs COLL Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, COLL has a market cap of 955.8M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while COLL trades at $27.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas COLL's P/E ratio is 3.70. In terms of profitability, ELAN's ROE is -0.03%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ELAN is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check COLL's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ELAN vs PETQ Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ELAN's ROE is -0.03%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ELAN is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ELAN vs AMPH Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, AMPH has a market cap of 916.3M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while AMPH trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas AMPH's P/E ratio is 7.09. In terms of profitability, ELAN's ROE is -0.03%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ELAN is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check AMPH's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ELAN vs IRWD Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while IRWD trades at $4.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas IRWD's P/E ratio is 5.54. In terms of profitability, ELAN's ROE is -0.03%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ELAN is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
ELAN vs EVO Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, EVO has a market cap of 710.5M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while EVO trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas EVO's P/E ratio is -2.82. In terms of profitability, ELAN's ROE is -0.03%, compared to EVO's ROE of -0.24%. Regarding short-term risk, ELAN is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ELAN vs BDSI Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ELAN's ROE is -0.03%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ELAN is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ELAN vs TLRY Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, TLRY has a market cap of 511.1M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while TLRY trades at $4.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas TLRY's P/E ratio is -7.21. In terms of profitability, ELAN's ROE is -0.03%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ELAN is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TLRY's competition here
Evolus, Inc. (NASDAQ: EOLS)
ELAN vs EOLS Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, EOLS has a market cap of 499.8M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while EOLS trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas EOLS's P/E ratio is -24.04. In terms of profitability, ELAN's ROE is -0.03%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ELAN is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ELAN vs AQST Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, AQST has a market cap of 494.3M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while AQST trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas AQST's P/E ratio is -6.46. In terms of profitability, ELAN's ROE is -0.03%, compared to AQST's ROE of +1.91%. Regarding short-term risk, ELAN is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check AQST's competition here
Kamada Ltd. (NASDAQ: KMDA)
ELAN vs KMDA Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, KMDA has a market cap of 419.4M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while KMDA trades at $7.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas KMDA's P/E ratio is 20.77. In terms of profitability, ELAN's ROE is -0.03%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ELAN is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ELAN vs CGC Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, CGC has a market cap of 409.5M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while CGC trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas CGC's P/E ratio is -0.58. In terms of profitability, ELAN's ROE is -0.03%, compared to CGC's ROE of -0.31%. Regarding short-term risk, ELAN is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ELAN vs TKNO Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, TKNO has a market cap of 346.3M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while TKNO trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas TKNO's P/E ratio is -20.84. In terms of profitability, ELAN's ROE is -0.03%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ELAN is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ELAN vs ALIM Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ELAN's ROE is -0.03%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ELAN is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
ELAN vs LNDC Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ELAN's ROE is -0.03%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ELAN is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check LNDC's competition here
Embecta Corp. (NASDAQ: EMBC)
ELAN vs EMBC Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, EMBC has a market cap of 262.2M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while EMBC trades at $4.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas EMBC's P/E ratio is 1.70. In terms of profitability, ELAN's ROE is -0.03%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, ELAN is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check EMBC's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
ELAN vs ORGO Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, ORGO has a market cap of 239.3M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while ORGO trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas ORGO's P/E ratio is 62.00. In terms of profitability, ELAN's ROE is -0.03%, compared to ORGO's ROE of -0.27%. Regarding short-term risk, ELAN is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
ELAN vs TYHT Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ELAN's ROE is -0.03%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ELAN is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ELAN vs SIGA Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, SIGA has a market cap of 218.8M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while SIGA trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas SIGA's P/E ratio is 11.30. In terms of profitability, ELAN's ROE is -0.03%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ELAN is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ELAN vs LFCR Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, LFCR has a market cap of 187.9M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while LFCR trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas LFCR's P/E ratio is -4.68. In terms of profitability, ELAN's ROE is -0.03%, compared to LFCR's ROE of -1.95%. Regarding short-term risk, ELAN is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check LFCR's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
ELAN vs ACB Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, ACB has a market cap of 185.2M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while ACB trades at $2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas ACB's P/E ratio is -6.10. In terms of profitability, ELAN's ROE is -0.03%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ELAN is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ACB's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ELAN vs REPH Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas REPH's P/E ratio is -8.04. In terms of profitability, ELAN's ROE is -0.03%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ELAN is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
ELAN vs DERM Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while DERM trades at $6.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas DERM's P/E ratio is -17.38. In terms of profitability, ELAN's ROE is -0.03%, compared to DERM's ROE of -0.36%. Regarding short-term risk, ELAN is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ELAN vs CRDL Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, CRDL has a market cap of 163.7M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while CRDL trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas CRDL's P/E ratio is -5.05. In terms of profitability, ELAN's ROE is -0.03%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, ELAN is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ELAN vs THTX Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas THTX's P/E ratio is -28.83. In terms of profitability, ELAN's ROE is -0.03%, compared to THTX's ROE of +0.17%. Regarding short-term risk, ELAN is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
ELAN vs ASRT Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ELAN's ROE is -0.03%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ELAN is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ASRT's competition here
Organigram Global Inc. (NASDAQ: OGI)
ELAN vs OGI Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, OGI has a market cap of 139.4M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while OGI trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas OGI's P/E ratio is -3.81. In terms of profitability, ELAN's ROE is -0.03%, compared to OGI's ROE of -0.07%. Regarding short-term risk, ELAN is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check OGI's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ELAN vs CPIX Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, CPIX has a market cap of 116.9M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while CPIX trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas CPIX's P/E ratio is -19.50. In terms of profitability, ELAN's ROE is -0.03%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ELAN is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ELAN vs SCTL Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ELAN's ROE is -0.03%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ELAN is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check SCTL's competition here
Procaps Group S.A. (NASDAQ: PROC)
ELAN vs PROC Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas PROC's P/E ratio is 1.53. In terms of profitability, ELAN's ROE is -0.03%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ELAN is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ELAN vs OPTN Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ELAN's ROE is -0.03%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ELAN is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
ELAN vs ZOM Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ELAN's ROE is -0.03%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ELAN is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ZOM's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
ELAN vs ZYBT Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, ZYBT has a market cap of 89.6M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while ZYBT trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas ZYBT's P/E ratio is -8.59. In terms of profitability, ELAN's ROE is -0.03%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, ELAN is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check ZYBT's competition here
Upexi, Inc. (NASDAQ: GRVI)
ELAN vs GRVI Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ELAN's ROE is -0.03%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, ELAN is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
ELAN vs ZYNE Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ELAN's ROE is -0.03%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ELAN is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ELAN vs SSIC Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ELAN's ROE is -0.03%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ELAN is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ELAN vs VLNS Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ELAN's ROE is -0.03%, compared to VLNS's ROE of N/A. Regarding short-term risk, ELAN is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check VLNS's competition here
BGM Group Ltd. (NASDAQ: BGM)
ELAN vs BGM Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, BGM has a market cap of 60.3M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas BGM's P/E ratio is -1.04. In terms of profitability, ELAN's ROE is -0.03%, compared to BGM's ROE of -0.07%. Regarding short-term risk, ELAN is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check BGM's competition here
DURECT Corporation (NASDAQ: DRRX)
ELAN vs DRRX Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ELAN's ROE is -0.03%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ELAN is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
ELAN vs INCR Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, INCR has a market cap of 58M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while INCR trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas INCR's P/E ratio is -2.26. In terms of profitability, ELAN's ROE is -0.03%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ELAN is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ELAN vs JUPW Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ELAN's ROE is -0.03%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, ELAN is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ELAN vs QLI Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas QLI's P/E ratio is -4.92. In terms of profitability, ELAN's ROE is -0.03%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ELAN is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
ELAN vs HEXO Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ELAN's ROE is -0.03%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ELAN is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check HEXO's competition here
Talphera, Inc. (NASDAQ: TLPH)
ELAN vs TLPH Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, TLPH has a market cap of 29.3M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while TLPH trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas TLPH's P/E ratio is -4.61. In terms of profitability, ELAN's ROE is -0.03%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, ELAN is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TLPH's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ELAN vs RMTI Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, RMTI has a market cap of 28.5M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while RMTI trades at $6.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas RMTI's P/E ratio is -6.89. In terms of profitability, ELAN's ROE is -0.03%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, ELAN is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ELAN vs AYTU Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while AYTU trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas AYTU's P/E ratio is -1.23. In terms of profitability, ELAN's ROE is -0.03%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, ELAN is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ELAN vs TXMD Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while TXMD trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas TXMD's P/E ratio is 105.45. In terms of profitability, ELAN's ROE is -0.03%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, ELAN is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ELAN vs CYTH Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ELAN's ROE is -0.03%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ELAN is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ELAN vs EVOK Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ELAN's ROE is -0.03%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ELAN is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check EVOK's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
ELAN vs BFRIW Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, BFRIW has a market cap of 17M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, ELAN's ROE is -0.03%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, ELAN is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check BFRIW's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ELAN vs OPTH Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, OPTH has a market cap of 16.3M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while OPTH trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas OPTH's P/E ratio is -18.56. In terms of profitability, ELAN's ROE is -0.03%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, ELAN is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ELAN vs ACRX Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ELAN's ROE is -0.03%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, ELAN is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check ACRX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
ELAN vs COSM Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, COSM has a market cap of 12.7M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while COSM trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas COSM's P/E ratio is -0.38. In terms of profitability, ELAN's ROE is -0.03%, compared to COSM's ROE of -0.96%. Regarding short-term risk, ELAN is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ELAN vs AGRX Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ELAN's ROE is -0.03%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ELAN is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ELAN vs NLTX Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ELAN's ROE is -0.03%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, ELAN is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
ELAN vs LCI Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas LCI's P/E ratio is -0.04. In terms of profitability, ELAN's ROE is -0.03%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ELAN is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ELAN vs ADMP Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ELAN's ROE is -0.03%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ELAN is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
ELAN vs YCBD Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, YCBD has a market cap of 5.9M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while YCBD trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas YCBD's P/E ratio is -1.38. In terms of profitability, ELAN's ROE is -0.03%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ELAN is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ELAN vs GELS Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, GELS has a market cap of 5M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while GELS trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas GELS's P/E ratio is -1.09. In terms of profitability, ELAN's ROE is -0.03%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ELAN is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
ELAN vs MNK Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas MNK's P/E ratio is -0.44. In terms of profitability, ELAN's ROE is -0.03%, compared to MNK's ROE of -0.26%. Regarding short-term risk, ELAN is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ELAN vs FLGC Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ELAN's ROE is -0.03%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ELAN is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check FLGC's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ELAN vs CPHI Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, CPHI has a market cap of 3.6M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while CPHI trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas CPHI's P/E ratio is -1.76. In terms of profitability, ELAN's ROE is -0.03%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, ELAN is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check CPHI's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
ELAN vs UPC Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, UPC has a market cap of 3.5M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while UPC trades at $7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas UPC's P/E ratio is -0.69. In terms of profitability, ELAN's ROE is -0.03%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ELAN is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
ELAN vs SBFM Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while SBFM trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas SBFM's P/E ratio is -0.20. In terms of profitability, ELAN's ROE is -0.03%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, ELAN is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check SBFM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
ELAN vs SHPH Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, SHPH has a market cap of 2.6M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while SHPH trades at $4.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas SHPH's P/E ratio is -0.20. In terms of profitability, ELAN's ROE is -0.03%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, ELAN is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check SHPH's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ELAN vs PLXP Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ELAN's ROE is -0.03%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ELAN is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check PLXP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ELAN vs SNOA Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, SNOA has a market cap of 2.4M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while SNOA trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas SNOA's P/E ratio is -1.22. In terms of profitability, ELAN's ROE is -0.03%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, ELAN is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check SNOA's competition here
Athenex, Inc. (NASDAQ: ATNX)
ELAN vs ATNX Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ELAN's ROE is -0.03%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ELAN is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ATNX's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
ELAN vs PROCW Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas PROCW's P/E ratio is N/A. In terms of profitability, ELAN's ROE is -0.03%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, ELAN is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
ELAN vs RDHL Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while RDHL trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas RDHL's P/E ratio is 0.12. In terms of profitability, ELAN's ROE is -0.03%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, ELAN is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check RDHL's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
ELAN vs YCBD-PA Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, ELAN's ROE is -0.03%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, ELAN is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
ELAN vs CYTHW Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas CYTHW's P/E ratio is N/A. In terms of profitability, ELAN's ROE is -0.03%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, ELAN is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check CYTHW's competition here
Lucy Scientific Discovery Inc. (NASDAQ: LSDI)
ELAN vs LSDI Comparison August 2026
Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELAN stands at 11B. In comparison, LSDI has a market cap of 906.9K. Regarding current trading prices, ELAN is priced at $22.46 on the NYSE, while LSDI trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELAN currently has a P/E ratio of 20.86, whereas LSDI's P/E ratio is -0.07. In terms of profitability, ELAN's ROE is -0.03%, compared to LSDI's ROE of +181.47%. Regarding short-term risk, ELAN is less volatile compared to LSDI. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check LSDI's competition here